LC3 and p62 as Diagnostic Markers of Drug-induced Autophagic Vacuolar Cardiomyopathy
Authors:
- Rodney D. McCombRMRodney D. McComb
- Bret C. MobleyBMBret C. Mobley
- Sakir Humayun GultekinSGSakir Humayun Gultekin
- Han S. LeeHLHan S. Lee
- Marta MargetaMMMarta Margeta
- 1 July 2013
- journal article
- case report
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 37 (7) , 1014-1021
Abstract
Autophagic vacuolar cardiomyopathy is an underrecognized, but potentially fatal, complication of treatment with chloroquine (CQ) and its derivative hydroxychloroquine (HCQ), which are used as therapy for malaria and common connective tissue disorders. Currently, the diagnosis of autophagic vacuolar cardiomyopathy is established through an endomyocardial biopsy and requires electron microscopy, which is not widely available and has a significant potential for sampling error. Recently, we have reported that immunohistochemistry for autophagic markers LC3 and p62 can replace electron microscopy in the diagnosis of HCQ-induced and colchicine-induced autophagic vacuolar skeletal myopathies. In the current study, we use 3 cases of CQ-induced or HCQ-induced cardiomyopathy and 1 HCQ-treated control case to show that the same two markers can be used to diagnose autophagic vacuolar cardiomyopathies by light microscopy. CQ-induced or HCQ-induced autophagic vacuolar cardiomyopathy is not universally fatal, but successful treatment requires early detection. By lowering the barriers to diagnosis, the application of these immunohistochemical markers will decrease the number of misdiagnosed patients, thus increasing the likelihood of favorable clinical outcomes.Keywords
This publication has 3 references indexed in Scilit:
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Mechanism of action of hydroxychloroquine as an antirheumatic drugSeminars in Arthritis and Rheumatism, 1993
- Pharmacologic actions of 4-aminoquinoline compoundsThe American Journal of Medicine, 1983